Xeljanz (tofacitinib) - Important Safety Information from Pfizer Healthcare Ireland as approved by HPRA

Notice type: 3rd Party Publications

Date: 28/03/2019

  

Problem Or Issue:
Important Safety Information communication from Pfizer Healthcare Ireland on increased risk of pulmonary embolism and mortality in rheumatoid arthritis patients receiving 10 mg twice daily in a clinical trial
 
Important Safety Information - Xeljanz (tofacitinib)



« Back